AbbVie's Acquisition Of Shire: Skepticism Creates Buying Opportunity
- AbbVie has agreed to buy Shire for $54B.
- One of the drivers for the acquisition was a tax inversion, which may be derailed due to political opposition.
- The acquisition has many other positive drivers, and will likely be consummated even without a tax inversion.
- The uncertainty surrounding the acquisition has provided a buying opportunity - in particular, options strategies offer good risk-reward.